Personalised medicine in rectal cancer : understanding and predicting response to neoadjuvant chemoradiotherapy
Around 12-15% of patients with locally advanced rectal cancer (LARC) undergo a pathologically complete response (Tumour Regression Grade 4 - TRG4) to neoadjuvant chemoradiotherapy; the remainder exhibit a spectrum of tumour regression (TRG1-3). Understanding therapy-related genomic alterations may h...
Main Author: | Alderdice, Matthew |
---|---|
Published: |
Queen's University Belfast
2017
|
Subjects: | |
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.725327 |
Similar Items
-
The prognostic role of extramural venous invasion in post-chemoradiotherapy rectal cancer
by: Chand, Manish
Published: (2015) -
Study of serial markers of biological response in rectal cancer patients receiving preoperative chemoradiotherapy with or without biological agents
by: Khan, A. A.
Published: (2017) -
Epithelial mesenchymal transition and resistance to neoadjuvant radiotherapy in locally advanced rectal cancer
by: Bhangu, Aneel
Published: (2014) -
The pathophysiological effects of adjuvant preoperative chemotherapy and/or radiotherapy on patients with advanced rectal cancer : 'neoadjuvant treatment is a two edged sword in patients with advanced colorectal cancer'
by: Rahmani, Samir
Published: (2013) -
Transcriptional signatures as early predictors of response in breast cancers treated with neoadjuvant aromatase inhibitors
by: Murray, Emma L.
Published: (2014)